Research Square (Research Square),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Aug. 17, 2023
Abstract
Prostate
cancer
(PCa)
is
a
non-cutaneous
malignancy
in
males
with
wide
variation
incidence
rates
across
the
globe.
It
second
most
reported
cause
of
death.
Its
etiology
may
have
been
linked
to
genetic
polymorphisms,
which
are
not
only
dominating
casualties
but
also
exerts
significant
effects
on
pharmacotherapy
outcomes.
Although
many
therapeutic
options
available,
suitable
candidates
identified
by
useful
biomarkers
can
exhibit
maximum
efficacy.
The
single-nucleotide
polymorphisms
(SNPs)
androgen
receptor
signaling
genes
influence
effectiveness
pathway
inhibitors
and
deprivation
therapy.
Furthermore,
SNPs
located
involved
transport,
drug
metabolism,
efflux
pumps
efficacy
pharmacotherapy.
Hence,
provide
basis
for
individualized
pharmacotherapeutic
PCa
include
hormonal
therapy,
chemotherapy
(Docetaxel,
Mitoxantrone,
Cabazitaxel,
Estramustine,
etc),
radiotherapy.
Here,
we
overview
impact
various
evaluate
current
an
emphasis
early
diagnosis
treatment
strategy
PCa.
Medicina,
Journal Year:
2024,
Volume and Issue:
60(12), P. 2032 - 2032
Published: Dec. 9, 2024
Background
and
Objectives:
Prostate
cancer
is
one
of
the
most
commonly
diagnosed
cancers
in
male
population
fifth
leading
cause
death
worldwide
men
as
2022.
One
potential
biomarkers
that
can
predict
progression
disease
transmembrane
adhesion
molecule
CD44s.
The
aims
this
study
were
to
determine
expression
CD44s
prostate
central
tumor
mass
periphery
compare
it
with
clinicopathological
parameters
(PSA,
Gleason
score,
surgical
margins,
biochemical
recurrence
disease)
patients
treated
radical
prostatectomy.
Materials
Methods:
research
was
randomized
retrospectively
during
period
from
2001
2006.
Tissue
microarrays
121
archival
acinar
carcinoma
samples
immunohistochemically
evaluated
for
expression.
immunoexpression
determined
semiquantitatively,
taking
into
account
percentage
(0
(0-5%),
1
(6-24%),
2
(26-75%),
3
(76-100%)
intensity
membranous
staining
cells
absent;
weak
at
400×;
intermediates
100×;
strong
40×)
calculated
obtain
a
final
score
(0-3
regarded
negative;
4-6
positive).
Results:
For
statistical
purposes,
we
divided
tumors
two
categories:
grade
group
makes
up
80.7%
2,
which
includes
all
remaining
groups
(out
2-5),
accounts
19.3%
tumors.
Grade
had
highest
incidence
4
(positive
expression).
There
statistically
significantly
more
positive
expressions
those
negative
prostatectomy
margins
(chi
square:
p
=
0.001;
Cramer
V:
0.319).
no
correlation
between
(p
0.218),
nor
preoperative
PSA
values
0.165).
In
tumors,
status
margin
related
0.028).
An
analysis
according
localization
part
on
did
not
show
significant
because
sample
too
small.
Descriptively,
be
noted
higher,
central/peripheral
ratio
higher
favor
periphery.
Conclusions:
Our
results
provide
insight
possible
value
predicting
behavior
justification
therapy
after
Also
hypothetically,
they
indicate
protective
role
well-differentiated
mass.
Therefore,
useful
further
sense.
Research Square (Research Square),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Aug. 17, 2023
Abstract
Prostate
cancer
(PCa)
is
a
non-cutaneous
malignancy
in
males
with
wide
variation
incidence
rates
across
the
globe.
It
second
most
reported
cause
of
death.
Its
etiology
may
have
been
linked
to
genetic
polymorphisms,
which
are
not
only
dominating
casualties
but
also
exerts
significant
effects
on
pharmacotherapy
outcomes.
Although
many
therapeutic
options
available,
suitable
candidates
identified
by
useful
biomarkers
can
exhibit
maximum
efficacy.
The
single-nucleotide
polymorphisms
(SNPs)
androgen
receptor
signaling
genes
influence
effectiveness
pathway
inhibitors
and
deprivation
therapy.
Furthermore,
SNPs
located
involved
transport,
drug
metabolism,
efflux
pumps
efficacy
pharmacotherapy.
Hence,
provide
basis
for
individualized
pharmacotherapeutic
PCa
include
hormonal
therapy,
chemotherapy
(Docetaxel,
Mitoxantrone,
Cabazitaxel,
Estramustine,
etc),
radiotherapy.
Here,
we
overview
impact
various
evaluate
current
an
emphasis
early
diagnosis
treatment
strategy
PCa.
